98552-54-6 Usage
Structure
Cyclic amino acid derivative 1-methylaminocyclohexane-1-carboxylic acid features a cyclic structure with an amino acid derivative attached to it.
Functional groups
1-methylaminocyclohexane moiety and carboxylic acid The compound contains a 1-methylaminocyclohexane group and a carboxylic acid functional group, which contribute to its chemical properties and reactivity.
Natural occurrence
Not found naturally in significant amounts 1-methylaminocyclohexane-1-carboxylic acid is not commonly found in nature, making it less abundant in comparison to other organic compounds.
Synthesis
Can be synthesized for pharmaceutical and chemical research Although not found naturally, the compound can be artificially synthesized and used in various research applications.
Potential applications
Treatment of neurological disorders and as a building block for other compounds 1-methylaminocyclohexane-1-carboxylic acid has been studied for its potential role in treating various neurological disorders and can also be used as a starting material for synthesizing other compounds.
Importance
Valuable for research and development in chemistry and pharmaceutical industries Due to its unique chemical properties and potential applications, 1-methylaminocyclohexane-1-carboxylic acid is considered an important compound for further research and development in both the chemistry and pharmaceutical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 98552-54-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,5,5 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 98552-54:
(7*9)+(6*8)+(5*5)+(4*5)+(3*2)+(2*5)+(1*4)=176
176 % 10 = 6
So 98552-54-6 is a valid CAS Registry Number.
98552-54-6Relevant academic research and scientific papers
Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4
-
Page/Page column 28, (2010/10/19)
Disclosed are compounds which bind VLA-4 and/or LPAM-1. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4 and/or LPAM-1. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
